medigraphic.com
ISSN 1561-3186 (Electronic)

2020, Number 3

<< Back Next >>

Rev Acta Médica 2020; 21 (3)

Respiratory Disease Exacerbated by Nonsteroidal Antiinflammatories: Current Knowledge and Trends

Ceballos RE, Báez LJM, Figueroa GI, Estruch FIM, Ginard CA

Language: Spanish
References: 63
Page: 1-30
PDF size: 512.96 Kb.


ABSTRACT

Introduction: Respiratory disease exacerbated by nonsteroidal antiinflammatories is a chronic disease resistant to treatment, characterized by the presence of eosinophilic rhinosinusitis, nasal polyposis, bronchial asthma and hypersensitivity to nonsteroidal antiinflammatories.
Objective: To deepen, with updated knowledge, about the diagnosis and treatment of this disease.
Methods: Comprehensive review of current evidence, based on recent publications about the subject, carried out during the period from November, 2019 to April, 2020, using search engines through scientific databases such as PubMed, SciElo, Research Gate, Scopus, ScienceDirect, and Google Scholar. Various sources such as magazines and electronic books published in Spanish and English were consulted.
Conclusions: Despite some advances in understanding the pathophysiology, respiratory disease exacerbated by nonsteroidal antiinflammatories remains a diagnostic and therapeutic challenge. Timely diagnosis will allow adequate multidisciplinary treatment and will avoid serious complications. Desensitization to aspirin is an effective and safe therapeutic option for optimal control of the disease.


REFERENCES

  1. Han J, Tan Y, Ann A, Hsu L. Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control: A possible oversight link. Resp Med 2016 [acceso: 03/03/2020]; 118:1-3. DOI: https://doi.org/10.1016/j.rmed.2016.07.004

  2. Tanya M, Laidlaw TM, Cahill KN. Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. J Allergy Clin Immunol Pract 2017 [acceso: 20/02/2020]; 5(3):537-45. Available in: https://www.sciencedirect.com/science/article/abs/pii/S2213219816305591

  3. Rodríguez JC, Jiménez F, Moreno-Paz J, Terán LM, Guaní-Guerra E. Aspirin exacerbated respiratory disease: Current topics and trends. Resp Med 2018 [acceso: 31/01/2020]; 135:62-75. Available in: https://www.sciencedirect.com/science/article/pii/S0954611118300039

  4. San Nicoló M, Högerle C, Gellrich D, Eder K, Pfrogner E, Gröger M. The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. Eur Arch Otorhinolaryngol 2020 [acceso: 13/01/2020]; 277(2):445-52. Available in: https://europepmc.org/article/med/31655881

  5. Agúndez JAG, Selinski S, Corsini E, Golka K, García-Martín E. Biomarkers in drug hypersensitivity. Front Pharmacol 2017 [acceso: 21/03/2020]; 8:348. DOI: https://doi.org/10.3389/fphar.2017.00348

  6. Cavkaytar O. Characteristics of NSAID‐induced hypersensitivity reactions in childhood. Ped Allergy Immunol 2018 [acceso: 20/02/2020]. 30(1) DOI: https://doi.org/10.1111/pai.12980

  7. 7.Laidlaw TM, Israel E. Aspirin-exacerbated respiratory disease. UpToDate 2020 [acceso: 1/04/2020] Available in: https://www.uptodate.com/contents/aspirin-exacerbated-respiratory-disease

  8. Jang DW, Comer BT, Lachanas VA, Kountakis SE. Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad. Laryngosc 2014 [acceso: 12/02/2020]; 124(1):34-7. DOI: https://doi.org/10.1002/lary.24220

  9. Stevens WW, Schleimer RP. Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. Immunol Allergy Clin N Am 2016 [acceso: 15/02/2020]; 36(4): 669-80. DOI: http://dx.doi.org/10.1016/j.iac.2016.06.004

  10. Arias Arcos MB. EREA: La enfermedad respiratoria exacerbada por aspirina. Rev Patol Resp 2019 [acceso: 12/0472020]; 22(2): 59-65. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/ibc-FGT-2141

  11. Méndez Sánchez A, Gutiérrez Martínez JR, Coca Pelaz A, Vázquez Piñera MA. Enfermedad respiratoria relacionada con aspirina tratada con mepolizumab en un paciente pediátrico. Arch Bronconeumol 2017 [acceso: 11/03/2020]; 55(1):55-7. DOI: https://doi.org/10.1016/j.arbres.2018.04.012

  12. Calderón JC, Dávila F, Mantilla R, Chérrez A, Calero E, Cabrera D, et al. Conocimiento y actitudes en médicos ecuatorianos sobre enfermedades respiratorias exacerbadas por aspirina. Rev. alerg. Méx 2017 [acceso: 02/04/2020]; 64(1) DOI: http://dx.doi.org/10.29262/ram.v64i1.219

  13. Ginard Cabanas A, Ceballos Rodríguez E, Báez López JM, Figueroa García I, Estruch Fajardo I. Caracterización de pacientes con enfermedad respiratoria exacerbada por el uso de la aspirina y otros antiinflamatorios no esteroideos. Rev Act Med 2019; 20(1) Disponible en: http://www.revactamedica.sld.cu/index.php/act/issue/view/1

  14. Yeung WY, Park HS. Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. Yonsei Med J 2020 [acceso: 20/01/2020]. 61(1):4-14 DOI: https://doi.org/10.3349/ymj.2020.61.1.4

  15. Duarte de Prato AA. Reacciones de hipersensibilidad a los antinflamatorios no esteroideos. Tesis doctoral 2010 [acceso: 14/02/2020]. Disponible en: https://www.tesisenred.net/handle/10803/10742#page=1

  16. Doña I, Pérez‐Sánchez N, Eguiluz‐Gracia I, Muñoz‐Cano R, Bartra J, Torres MJ, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti‐inflammatory drugs. J Allergy 2020 [acceso: 03/03/2020]; 75(3):561-75. DOI: https://doi.org/10.1111/all.14032

  17. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med 2018 [acceso: 03/03/2020]; 379: 1060-70. DOI: https://doi.org/10.1056/NEJMra1712125

  18. Wongsa Ch, Sompornrattanaphan M, Tantilipikorn P, Thongngarm T. Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease. Asian Pac J Allergy Immunol 2019 [acceso: 28/02/2020]. DOI: https://doi.org/10.12932/ap-150619-0583

  19. Laidlaw T.M., Levy, J.M. NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets. Curr Allergy Asth Rep 2020 [acceso: 16/02/2020]; 20(4):10. DOI: https://doi.org/10.1007/s11882-020-00905-9

  20. 20.- Arikoglu T, Aslan G, Yildirim D , BirgulBatmaz S , Kuyucu S. Discrepancies in the diagnosis and classification of nonsteroidal anti-inflammatory drug hypersensitivity reactions in children. Allergol Intern 2017 [acceso: 25/01/2020]; 66(3):418-24. DOI: https://doi.org/10.1016/j.alit.2016.10.004

  21. Izquierdo-Domínguez A, Campo P, Torres MJ, Dordal MT. Statement of the spanish society of allergology and clinical immunology on provocation tests with aspirin/nonsteroidal anti-inflammatory drugs. J Invest Allergol Clin Immunol 2020 [acceso: 31/01/2020]; 30(1):1-13. DOI: https://doi.org/10.18176/jiaci.0449

  22. Doña I, Barrionuevo E, Salas M, Laguna JJ, Agondez J, García-Martín E, et al. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Sci Rep 2018 [acceso: 12/02/2020]; 8,16710. DOI: https://doi.org/10.1038/s41598-018-34668-1

  23. Ayuso P, Plaza-Serón MC, López NB, Doña I, Campo P, Canto G, et al. Genetic variants in arachidonic acid pathway genes associated with NSAID-exacerbated respiratory disease. Pharmacogen 2015 [acceso: 13/02/2020]; 16(8) DOI: https://doi.org/10.2217/pgs.15.43)

  24. Calvo Campoverde K, Giner-Muñoz MT, Martínez Valdez L, Rojas Volquez M, Lozano Blasco J, Machinena A, et al. Reacciones de hipersensibilidad a antiinflamatorios no esteroideos y su tolerancia a fármacos alternativos. An Pediatr (Barc) 2016 [acceso: 21 mar 2020]; 84(3):148-53. DOI: https://doi.org/10.1016/j.anpedi.2015.05.004

  25. Plaza Seron MC. Reacciones de hipersensibilidad por intolerancia cruzada a antiinflamatorios no esteroideos: relacion fenotipo-genotipo. Tesis doctoral 2016 [acceso: 14/03/2020] Disponible en: https://riuma.uma.es/xmlui/bitstream/handle/10630/13245/TD_PLAZA_SERON_Maria_del_Carmen.pdf?sequence=1&isAllowed=y

  26. Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E. Aspirin exacerbated respiratory disease: Current topics and trends. Resp Med 2018 [acceso: 26/04/2020]; 135: 62-75. DOI: https://doi.org/10.1016/j.rmed.2018.01.002

  27. Sarraquigne MP, Mariño AI, Saranz R, Colella M, López K, Bovina Martijena MP et al. Alergia e intolerancia a antiinflamatorios no esteroideos en pediatría. Arch Arg Pediatr 2020 [acceso: 29/04/2020]; 118(1):S1-S11. DOI: http://dx.doi.org/10.5546/aap.2020.S1

  28. Cortellini G, Caruso C, Romano A. Aspirin challenge and desensitization: how, when and why. Curr Opin Allergy Clin Immunol 2017 [acceso: 02/05/2020];17(4):247-54. DOI: https://doi.org/10.1097/ACI.0000000000000374

  29. Lee EY, Teitelbaum D, Chiam M, Vadas P. Characterization of Patients with Ibuprofen Hypersensitivity. Int Arch Allergy Immunol 2019 [acceso: 28/04/2020]; 178(2): 177-81. DOI: https://doi.org/10.1159/000494388

  30. Rivera Reigada ML. Estudio farmacogenético de reacciones de hipersensibilidad a antibióticos beta-lactámicos y a antiinflamatorios no esteroideos. Tesis doctoral 2015. [acceso: 20/02/2020]. Disponible en: https://gredos.usal.es/bitstream/handle/10366/128266/DCBD_RiveraReigadaML_Estudiofarmacogen%E9tico.pdf;jsessionid=3F5C640F055E90EF6D804B9450697CC6?sequence=1

  31. Pham DL, Kim JH, Trinh TH, Park HS. What we know about nonsteroidal anti-inflammatory drug hypersensitivity. Korean J Intern Med 2016 [acceso: 11 mar 2020]; 31(3): 417-32. DOI: https://doi.org/10.3904/kjim.2016.085

  32. Fuertes Ferre G, Cruz Ferrer GM, Calvo Cebollero I. Desensibilización al ácido acetil salicílico en la nueva era del intervencionismo coronario percutáneo. Med Clin (Barc) 2015 [acceso: 02/03/2020];145(6):253-7 Disponible en: https://kundoc.com/pdf-desensibilizacion-al-acido-acetil-salicilico-en-la-nueva-era-del-intervencionism.html

  33. Ponvert C. Les réactions d’hypersensibilité aux antalgiques non opiacés, antipyrétiques et anti-inflammatoires non stéroïdiens. Rev Fr Allergol 2020 [acceso: 19/02/2020]. DOI: https://doi.org/10.1016/j.reval.2020.01.003

  34. Bobolea I, del Pozo V, Sanz V, Cabañas R, Fiandord A, Alfonso-Carrilloe C, et al. Aspirin desensitization in aspirin-exacerbated respiratory disease: New insights into the molecular mechanisms. Resp Med 2018 [acceso: 03/03/2020]; 143:39-41. DOI: https://doi.org/10.1016/j.rmed.2018.08.009

  35. Solomon DH. Overview of COX-2 selective NSAIDs. UpToDate 2020 [acceso: 11/05/2020]. Available in: https://www.uptodate.com/contents/overview-of-cox-2-selective-nsaids

  36. Lee K., Lee SH., Kim TH. The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy. Int J Mol Sci 2020 [acceso: 05/04/2020]; 21(5), [1851]. DOI: https://doi.org/10.3390/ijms21051851)

  37. Holguín-Gómez L, Vásquez-Ochoa LA, Cardona R. Angioedema. Rev Alerg Mex 2016 [acceso: 15/01/2020];63(4):373-84. Disponible en: http://revistaalergia.mx/ojs/index.php/ram/article/viewFile/220/362

  38. Simon RA. NSAIDs (including aspirin): Allergic and pseudoallergic reactions. UpToDate 2018 [acceso: 12/03/2020] Available in: https://www.uptodate.com/contents/nsaids-including-aspirin-allergic-and-pseudoallergic-reactions

  39. Laidlaw TM. Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease. World J Otorhinolaryngol - H N Surg 2018 [acceso: 05/04/2020]; 4(3):162-8. DOI: https://doi.org/10.1016/j.wjorl.2018.08.001

  40. Taniguchi M, Mitsui Ch, Hayashi H, Ono E, Kajiwara K, Mita H, et al. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. Allergol Int 2019 [acceso: 09/02/2020]; 68(3):289-95. DOI: https://doi.org/10.1016/j.alit.2019.05.001

  41. Solomon DH. Nonselective NSAIDs: Overview of adverse effects. UpToDate 2020 [acceso: 11/05/2020] Available in: https://www.uptodate.com/contents/nonselective-nsaids-overview-of-adverse-effects

  42. Le Pham D, Lee JH, Park HS. Aspirin-exacerbated respiratory disease: an update. Curr Opin Pulm med 2017 [acceso: 11/05/2020]; 23(1):89-96(8), DOI: https://doi.org/10.1097/MCP.0000000000000328

  43. Sung-dong K, Kyu-Sup Ch. Samter’s triad: state of the art. Clin Exp Otorhinolaryngol 2018 [acceso: 05/01/2020]; 11(2):71-80. DOI: https://doi.org/10.21053/ceo.2017.01606

  44. Kowalski, ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)-a EAACI position paper. Eur J Allergy Clin Inmunol 2018 [acceso: 09/03/2020]; 74(1):28-39. DOI: https://doi.org/10.1111/all.13599

  45. Ledford DK., Lockey RF. Aspirin or Nonsteroidal Anti-inflammatory Drug–Exacerbated Chronic Rhinosinusitis. J Allergy Clin Immunol Prac 2016 [acceso: 19/02/2020]; 4(4):590-8 DOI: https://doi.org/10.1016/j.jaip.2016.04.011

  46. Adappa ND, Ranasinghe VJ, Trope M, Brooks SG, Glicksman JT, Parasher AK et al. Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol 2018 [acceso: 26/03/2020]; 8(1):49-53. DOI: https://doi.org/10.1002/alr.22036

  47. Studer M.B. Roland LT, Ochsner MC, Cox D, DelGaudio JM, Wise SK, et al. Aspirin-Exacerbated Respiratory Disease With Allergic Fungal Rhinosinusitis: A Case Series of Overlapping Sinonasal Endotypes. Am J Rhinol Allergy 2020 [acceso: 14/02/2020] DOI: https://doi.org/10.1177/1945892420903587

  48. Le Pham D, Lee JH, Park HS. Aspirin-exacerbated respiratory disease: An update.Curr Opin Pulm Med 2017 [acceso: 04/04/2020]; 23(1):89-96. DOI: https://doi.org/10.1097/MCP.0000000000000328

  49. Woessner KM. Update on aspirin-exacerbated respiratory disease. Curr Allergy Asthma Rep 2017 [acceso: 29/01/2020]; 17(2) DOI: https://doi.org/10.1007/s11882-017-0673-6

  50. Cahill KN, Johns CB, Cui J, Wichner P, Bates DV, Laidlaw TM, et al. Automated identification of an aspirin-exacerbated respiratory disease cohort. J Allergy Clin Immunol 2017 [acceso: 23/02/2020]; 139(3):819-25.e6 DOI: https://doi.org/10.1016/j.jaci.2016.05.048

  51. Castillo Vizuete JA, Sastre J, del Cuvillo Bernal A, Picado C, Martínez Moragón E, Ignacio García JM et al. Rinitis, poliposis nasal y su relación con el asma. Arch Bronconeumol 2018 [acceso: 15/02/2020]; 55(3):146-55 DOI: https://doi.org/10.1016/j.arbres.2018.09.0019

  52. Park H, Choi Y, Jung CG, Park HS. Potential biomarkers for NSAID-exacerbated respiratory disease. Mediat Inflam 2017 [acceso: 04/04/2020]; 2017: 8160148. Available in: https://doi.org/10.1155/2017/8160148

  53. Lee JH, Jung CG, Park HS. An update on the management of aspirin-exacerbated respiratory disease. Expert J Resp Med 2018 [acceso: 13/01/2020]; 12(2):137-43 DOI: https://doi.org/10.1080/17476348.2018.1417843

  54. Juri MC, fernández DS, Larrauri B, Malbrán E, Torre G, Malbrán A. Alergia a drogas. experiencia en 771 procedimientos. Medic 2017 [acceso: 20/03/2020]; 77(3):180-4. Disponible en: https://medicinabuenosaires.com/revistas/vol77-17/n3/180-184-Med77-1-6546-Juri.pdf

  55. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinop-hil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Resp Med 2016 [acceso: 14/02/2020]; 4(7):549-56 DOI: https://doi.org/10.1016/S2213-2600(16)30031-5

  56. Simon RA, Cutlip D. Introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions. UpToDate 2018 [acceso: 28/03/2020] Available in: https://www.uptodate.com/contents/introduction-of-aspirin-to-patients-with-aspirin-hypersensitivity-requiring-cardiovascular-interventions

  57. Xu JJ, Sowerby L, Rotenberg BW. Aspirin desensitization for aspirin-exacerbated respiratory disease (Samter's Triad): a systematic review of the literature. Int Forum Allergy Rhinol 2013 [acceso: 05/05/2020]; 3(11):915-20. DOI: https://doi.org/10.1002/alr.21202

  58. Tajudeen B, Schwartz JS, Bosso JV. The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease. Curr Opin Otolaryngol H N Surg 2017 [acceso: 15/02/2020]; 25(1):30-4 Available in: https://doi.org/10.1097/moo.0000000000000331

  59. 59.Simon RA. Diagnostic challenge and desensitization protocols for NSAID reactions. UpToDate 2019 [acceso: 15/05/2020] Available in: https://www.uptodate.com/contents/diagnostic-challenge-and-desensitization-protocols-for-nsaid-reactions

  60. Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. Resp med 2016 [acceso: 05/02/2020]; 118:96-101. DOI: https://doi.org/10.1016/j.rmed.2016.07.017

  61. Williams AN. Diagnostic Evaluation in Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am 2016 [acceso: 12/01/2020]; 36(4):657-68. DOI: https://doi.org/10.1016/j.iac.2016.06.003

  62. Simon RA. Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization. UpToDate 2020 [acceso: 13/03/2020] Available in: https://www.uptodate.com/contents/aspirin-exacerbated-respiratory-disease-nsaid-challenge-and-desensitization

  63. Walters KM, Waldram JD, Woessner KM, White AA. Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease. Am J Rhinol Allergy 2018 [acceso: 15/05/2020]; 32: 280-6. DOI: https://doi.org/10.1177/1945892418770260




2020     |     www.medigraphic.com